bluebird bio (NASDAQ:BLUE) and Outlook Therapeutics (NASDAQ:OTLK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Profitability
This table compares bluebird bio and Outlook Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bluebird bio | -1,326.56% | -42.29% | -34.48% |
| Outlook Therapeutics | -423.83% | N/A | -125.97% |
Volatility & Risk
bluebird bio has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for bluebird bio and Outlook Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bluebird bio | 0 | 6 | 12 | 0 | 2.67 |
| Outlook Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
bluebird bio presently has a consensus target price of $134.99, suggesting a potential upside of 50.24%. Outlook Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 682.61%. Given Outlook Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than bluebird bio.
Institutional & Insider Ownership
3.4% of Outlook Therapeutics shares are owned by institutional investors. 3.0% of bluebird bio shares are owned by company insiders. Comparatively, 4.0% of Outlook Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares bluebird bio and Outlook Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bluebird bio | $54.58 million | 91.08 | -$555.63 million | ($10.68) | -8.41 |
| Outlook Therapeutics | $8.15 million | 3.98 | -$30.09 million | ($1.98) | -0.58 |
Outlook Therapeutics has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Outlook Therapeutics beats bluebird bio on 9 of the 14 factors compared between the two stocks.
About bluebird bio
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
About Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Receive News & Ratings for bluebird bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for bluebird bio and related companies with MarketBeat.com’s FREE daily email newsletter.
